May 10, 2005. What's the serial number? RC designed pretty much all of their frames for a few years. It could be a Colorado, Pinnacle, or a few others. I have a LBS that has a few standard framed Nishiki's from that era with the cunningham designed business. I'll swing by sometime in the next few days and get the frame. WELCOME TO THE BICYCLE MUSEUM. Bicycles are wonderfully simple, eloquent and efficient machines. A few of the bikes were purchased by me, or for me, new, including. Sep 18, 2009. Also, where are the serial numbers located on nishiki bikes? I couldn't find any on the bottom of the BB, nor on the inside of the chainstays.are the numbers hiding from me? Speaking of serial numbers, i can't find any on the derailleurs either.wtf d00d? I ride a 26'er with tubes and rim brakes.

Adobe Flash Player is required to view this feature. Cyberlink Powerdirector 12 Slideshow Templates Download. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Original Article A Single Intravenous Infusion of Gamma Globulin as Compared with Four Infusions in the Treatment of Acute Kawasaki Syndrome Jane W. Newburger, M.D., Masato Takahashi, M.D., Alexa S.

Beiser, Ph.D., Jane C. Burns, M.D., John Bastian, M.D., Kyung Ja Chung, M.D., Steven D. Colan, M.D., C. Elise Duffy, M.D., David R.

Fulton, M.D., Mary P. Glode, M.D., Wilbert H. Mason, M.D., H. Cody Meissner, M.D., Anne H. Rowley, M.D., Stanford T. Shulman, M.D., Venudhar Reddy, M.D., Robert P.

Sundel, M.D., James W. Wiggins, M.D., Theodore Colton, Sc.D., Marian E. Melish, M.D., and Fred S. N Engl J Med 1991; 324:1633-1639 DOI: 10.1056/NEJM42305. The relative prevalence of coronary abnormalities, adjusted for age and sex, among patients treated with the four-day regimen, as compared with those treated with the single-infusion regimen, was 1.94 (95 percent confidence limits, 1.01 and 3.71) two weeks after enrollment and 1.84 (95 percent confidence limits, 0.89 and 3.82) seven weeks after enrollment. Children treated with the single-infusion regimen had lower mean temperatures while hospitalized (day 2, P.

Kawasaki syndrome is an acute illness of childhood characterized by fever, rash, conjunctivitis, inflammation of the mucous membranes, swollen erythematous hands and feet, and cervical adenopathy., The histopathological features of vasculitis involving arterioles, capillaries, and venules appear in the earliest phase of the disease. Subsequently, the walls of the coronary arteries and other medium-sized muscular arteries may show evidence of focal segmental destruction, with coronary-artery aneurysms or ectasia developing in approximately 15 to 25 percent of affected children. Studies in Japan suggested that the intravenous administration of gamma globulin during the acute phase of Kawasaki syndrome decreased the prevalence of coronary-artery lesions.

On the basis of these observations, we conducted a multicenter, randomized trial in the United States. Gamma globulin administered in four consecutive daily doses, together with aspirin, resulted in a marked reduction in the prevalence of coronary-artery abnormalities as compared with aspirin alone.

Furthermore, this treatment had a rapid and dramatic antiinflammatory effect. Motivated by the potential economic and social benefits of shortening the hospital stay for patients with Kawasaki syndrome, we organized a second multicenter, randomized trial to ascertain whether the administration of intravenous gamma globulin in a single large dose would have similar or better efficacy and safety than the standard regimen of four daily doses. Enrollment of Patients We enrolled patients from May 1986 through November 1989 at seven centers in the United States. We defined cases of Kawasaki syndrome according to the following criteria: fever; nonexudative conjunctival injection; changes in the oral pharynx, including mucosal erythema, dry, fissured lips, and 'strawberry tongue'; changes in the extremities, characteristically erythema of the palms and soles, edema of the hands and feet, or periungual desquamation in the subacute phase of the disease; rash; and cervical adenopathy (one or more nodes at least 1.5 cm in diameter). The criteria for entry into the study required that patients have fever plus four of the other five signs and have no clinical or laboratory evidence of any other disease known to mimic Kawasaki syndrome. We also required that eligible patients be enrolled within 10 days of the onset of illness, with day 1 defined as the first day of fever. Patients could not have received treatment with gamma globulin before referral to the study center.